Prevention of hepatorenal syndrome in patients with cirrhosis and ascites: a pilot randomized control trial between pentoxifylline and placebo

No abstract is available for this paper.

• Publication year

  2011

• Venue

  European Journal of Gastroenterology and Hepathology

• Publication date

  2011-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/MEG.0b013e3283435d76PMID 21285885
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis.

  2010cited by this paper
• Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: A randomized, placebo-controlled study

  2009cited by this paper
• A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome.

  2008cited by this paper
• Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study.

  2008cited by this paper
• Terlipressin and Albumin in Patients with Cirrhosis and Type I Hepatorenal Syndrome

  2008cited by this paper
• Terlipressin and Albumin vs Albumin in Patients with Cirrhosis and Hepatorenal Syndrome: A Randomized Study

  2008cited by this paper
• An Open Label, Pilot, Randomized Controlled Trial of Noradrenaline Versus Terlipressin in the Treatment of Type 1 Hepatorenal Syndrome and Predictors of Response

  2008cited by this paper
• Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.

  2008cited by this paper
• Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis

  2007cited by this paper
• Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis.

  2007cited by this paper
• Amelioration of Steatohepatitis with Pentoxifylline in a Novel Nonalcoholic Steatohepatitis Model Induced by High-Fat Diet

  2007cited by this paper
• Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non‐alcoholic steatohepatitis

  2006cited by this paper
• Upregulation of TNF-alpha production signaling pathways in monocytes from patients with advanced cirrhosis: possible role of Akt and IRAK-M.

  2006cited by this paper
• Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study.

  2005cited by this paper
• Prevention of hepatopulmonary syndrome and hyperdynamic state by pentoxifylline in cirrhotic rats

  2004cited by this paper
• Management of adult patients with ascites due to cirrhosis

  2004cited by this paper
• Beneficial effects of terlipressin in hepatorenal syndrome: A prospective, randomized placebo‐controlled clinical trial

  2003cited by this paper
• Hepatorenal syndrome: diagnostic accuracy, clinical features, and outcome in a tertiary care center

  2002cited by this paper
• Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: A pilot study

  2002cited by this paper
• Molecular and structural consequences of early renal allograft injury.

  2002cited by this paper
• Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial.

  2000cited by this paper
• Effects of pentoxifylline, pentifylline and gamma-interferon on proliferation, differentiation, and matrix synthesis of human renal fibroblasts.

  2000cited by this paper
• Pentoxifylline Reduces in vitro Renal Myofibroblast Proliferation and Collagen Secretion

  2000cited by this paper
• Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis.

  1999cited by this paper
• Development of quinolone-resistant strains of Escherichia coli in stools of patients with cirrhosis undergoing norfloxacin prophylaxis: clinical consequences.

  1999cited by this paper
• Treatment of acute renal failure.

  1998cited by this paper
• [Treatment of acute renal failure].

  1998cited by this paper
• Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin

  1997cited by this paper
• Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis

  1996cited by this paper
• Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club.

  1996cited by this paper
• Chracteristics of the infections caused by Escherichia coli resistant, to norfloxacin in hospitalized cirrhotic patients

  1995cited by this paper
• Pentoxifylline for Intermittent Claudication

  1994cited by this paper
• Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis

  1994cited by this paper
• Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites.

  1993cited by this paper
• Tumor necrosis factor alpha and interleukin 6 plasma levels in infected cirrhotic patients.

  1993cited by this paper
• Increased tumor necrosis factor production by monocytes in alcoholic hepatitis

  1989cited by this paper
• Limitations of creatinine in quantifying the severity of cyclosporine-induced chronic nephropathy.

  1986cited by this paper
• Prediction of creatinine clearance from serum creatinine.

  1975cited by this paper

• Hovenia dulcis: a Chinese medicine that plays an essential role in alcohol-associated liver disease

  2024cites this paper
• Etiological Spectrum of Cirrhosis in India: A Systematic Review and Meta-analysis.

  2023cites this paper
• Clinical Significance and Management of Hyponatremia in Liver Cirrhosis

  2023cites this paper
• Design of a multicenter randomized clinical trial for treatment of Alcohol-Associated Hepatitis

  2023cites this paper
• Update on hepatorenal Syndrome: Definition, Pathogenesis, and management.

  2022cites this paper
• IL‐1 receptor antagonist plus pentoxifylline and zinc for severe alcohol‐associated hepatitis

  2022cites this paper
• Hepatorenal Syndrome: Definitions, Diagnosis, and Management.

  2022cites this paper
• Фармакотерапія цирозу печінки та його ускладнень

  2021cites this paper
• Intestinal SIRT1 Deficiency-Related Intestinal Inflammation and Dysbiosis Aggravate TNFα-Mediated Renal Dysfunction in Cirrhotic Ascitic Mice

  2021influential citation
• Acute-on-Chronic Liver Failure: Pathophysiological Mechanisms and Management

  2021cites this paper
• A Review for the Practicing Clinician: Hepatorenal Syndrome, a Form of Acute Kidney Injury, in Patients with Cirrhosis

  2021cites this paper
• Clinical Practice of Hepatorenal Syndrome: A Brief Review on Diagnosis and Management

  2021cites this paper
• Liver Cirrhosis: Modern Approach to the Problem

  2020cites this paper
• Design and rationale of a multicenter defeat alcoholic steatohepatitis trial: (DASH) randomized clinical trial to treat alcohol-associated hepatitis.

  2020cites this paper
• Reexamining the data used in the 2012 guidelines of the American Association for the Study of Liver Diseases for the management of adult patients with ascites due to cirrhosis

  2019cites this paper
• Treatment of Type-1 Hepatorenal Syndrome with Pentoxifylline: A Randomized Placebo Controlled Clinical Trial.

  2018cites this paper
• Impact of Propranolol on Preventing Renal Dysfunction in Patients with Cirrhosis

  2017cites this paper
• Cytokines in Hepatic Injury

  2017cites this paper
• New Developments in Hepatorenal Syndrome

  2017cites this paper
• DECOMPENSATED CIRRHOSIS; THYROID HORMONE LEVELS IN PATIENTS

  2016cites this paper
• Pathogenesis of Hepatorenal Syndrome: Implications for Therapy.

  2016cites this paper
• Hepatorenal Syndrome: A Review of Pathophysiology and Current Treatment Options

  2015cites this paper
• Predictors of hepatorenal syndrome in alcoholic liver cirrhosis.

  2015cites this paper
• Perioperative Risk Assessment and Management of Cirrhotic Patients

  2015influential citation
• Management of hepatorenal syndrome.

  2015cites this paper
• Hepatorenal Syndrome: Aetiology, Diagnosis, and Treatment

  2015cites this paper
• Cirrhosis and its complications: evidence based treatment.

  2014cites this paper
• Antioxidant adaptations in liver fibrogenesis

  2014cites this paper
• Current treatment options for alcohol-related liver disease

  2014cites this paper
• Risk factors and outcome of bacterial infections in cirrhosis.

  2014cites this paper
• Preventive effect of pentoxifylline on contrast-induced acute kidney injury in hypercholesterolemic rats

  2014cites this paper
• WJG 20 th Anniversary Special Issues ( 11 ) : Cirrhosis Cirrhosis and its complications : Evidence based treatment

  2014cites this paper
• TOPIC HIGHLIGHT

  2014cites this paper
• Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012

  2013cites this paper
• The preventive effect of pentoxifylline on contrast-induced nephropathy: a randomized clinical trial

  2013cites this paper
• Serum Sodium Identifies Patients with Cirrhosis at High Risk of Hepatorenal Syndrome

  2013cites this paper
• тр УднОсти и нОВые дОстиЖения В диАгнОстике, Пр ОфилАктике и лечении геПА тОренА льнОг О синдр ОмА

  2013cites this paper
• Alcoholic Hepatitis: Steroids vs. Pentoxifylline

  2013cites this paper
• Management of liver cirrhosis in patients with hepatocellular carcinoma.

  2013cites this paper
• Management bei schwerer alkoholischer Hepatitis

  2013cites this paper
• On the role of pentoxifylline versus other TNF-alpha inhibitors in the prevention of hepatorenal syndrome.

  2012cites this paper
• Complications of cirrhosis

  2012cites this paper
• Potential role of TNF alpha blockers in delaying the progression of hepato-renal syndrome.

  2012cites this paper
• Kidneys in chronic liver diseases.

  2012cites this paper
• Management of alcoholic hepatitis.

  2012cites this paper